Orthofix Medical (OFIX)
Market Price (9/1/2026): $9.57 | Market Cap: $391.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
Orthofix Medical (OFIX)
Market Price (9/1/2026): $9.57Market Cap: $391.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Biotechnology & Genomics. Themes include Geriatric Care, and Orthopedic Biologics. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.5% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.3% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% Key risksOFIX key risks include [1] significant merger integration challenges, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Biotechnology & Genomics. Themes include Geriatric Care, and Orthopedic Biologics. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4.5% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 24x |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.3% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksOFIX key risks include [1] significant merger integration challenges, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Orthofix Medical (OFIX) stock has remained largely at the same level since 5/31/2026 because of the following key factors:
1. Mixed fiscal Q2 2026 financial results with a widened net loss impacted investor sentiment. Orthofix Medical reported net sales of $210.9 million for fiscal Q2 2026 (ended June 30, 2026), marking a 4% increase on a reported basis and 5% on a pro forma constant currency basis compared to fiscal Q2 2025, which slightly surpassed analyst estimates of $209.28 million. However, the company's net loss widened to $15.8 million, or $0.39 per share, in fiscal Q2 2026, compared to a net loss of $14.1 million, or $0.36 per share, in the prior year period. This mixed performance, particularly the increased net loss, contributed to a significant stock price drop of approximately 15% on August 5, 2026, following the earnings release.
2. Concerns regarding a one-off revenue boost and anticipated future headwinds introduced investor caution. A key factor contributing to the stock's post-earnings decline and subsequent stabilization at a lower level was the disclosure of a European distributor inventory purchase. This arrangement is expected to contribute approximately $15 million in incremental net sales to Orthofix Medical in fiscal 2026, with the majority recognized in fiscal Q4. However, management also projected this would create an approximate $22 million net sales headwind in fiscal 2027, signaling that a portion of the current growth is not sustainable. This "one-off" nature of revenue generation heightened investor worries about the fragility and long-term quality of the company's growth.
Show more
Orthofix Medical (OFIX) stock has remained largely at the same level since 5/31/2026 because of the following key factors:
1. Mixed fiscal Q2 2026 financial results with a widened net loss impacted investor sentiment. Orthofix Medical reported net sales of $210.9 million for fiscal Q2 2026 (ended June 30, 2026), marking a 4% increase on a reported basis and 5% on a pro forma constant currency basis compared to fiscal Q2 2025, which slightly surpassed analyst estimates of $209.28 million. However, the company's net loss widened to $15.8 million, or $0.39 per share, in fiscal Q2 2026, compared to a net loss of $14.1 million, or $0.36 per share, in the prior year period. This mixed performance, particularly the increased net loss, contributed to a significant stock price drop of approximately 15% on August 5, 2026, following the earnings release.
2. Concerns regarding a one-off revenue boost and anticipated future headwinds introduced investor caution. A key factor contributing to the stock's post-earnings decline and subsequent stabilization at a lower level was the disclosure of a European distributor inventory purchase. This arrangement is expected to contribute approximately $15 million in incremental net sales to Orthofix Medical in fiscal 2026, with the majority recognized in fiscal Q4. However, management also projected this would create an approximate $22 million net sales headwind in fiscal 2027, signaling that a portion of the current growth is not sustainable. This "one-off" nature of revenue generation heightened investor worries about the fragility and long-term quality of the company's growth.
3. Post-earnings analyst downgrades and price target reductions reflected increased skepticism. Following the fiscal Q2 2026 earnings announcement, several Wall Street analysts lowered their price targets for Orthofix Medical. For instance, Stifel Nicolaus reduced its price target from $15 to $13, and Canaccord Genuity decreased its target from $18 to $13. The average analyst rating also shifted towards a "Hold" consensus from previous "Buy" sentiments. These adjustments reflected a more cautious outlook on the company's valuation and growth prospects, contributing to the stock's downward correction and consolidation at a reduced price level.
4. Raised full-year guidance and segment-specific growth provided underlying support, preventing further significant decline. Despite the aforementioned concerns, Orthofix Medical raised its full-year 2026 net sales guidance to a range of $845 million to $855 million, an increase of $7 million at both ends from previous guidance. Additionally, the company increased its non-GAAP adjusted EBITDA guidance to $95 million to $98 million. The company also reported positive operational highlights, including double-digit constant currency growth in its Global Spine Fixation and Global Limb Reconstruction segments, stabilization in Biologics, and the restoration of Medicare reimbursement for bone growth stimulators, which improves visibility for the Therapeutic Solutions business in the second half of the year. These positive developments and an improved full-year outlook offered a floor to the stock price, leading to its relative stability within a new, lower trading range after the initial post-earnings drop.
Show less
Stock Movement Drivers
Fundamental Drivers
The 1.3% change in OFIX stock from 5/31/2026 to 8/31/2026 was primarily driven by a 1.5% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 8312026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.27 | 9.39 | 1.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 825 | 833 | 0.9% |
| P/S Multiple | 0.5 | 0.5 | 1.5% |
| Shares Outstanding (Mil) | 40 | 41 | -1.1% |
| Cumulative Contribution | 1.3% |
Market Drivers
5/31/2026 to 8/31/2026| Return | Correlation | |
|---|---|---|
| OFIX | 1.3% | |
| Market (SPY) | 1.4% | 1.8% |
| Sector (XLV) | 14.1% | 28.2% |
Fundamental Drivers
The -30.6% change in OFIX stock from 2/28/2026 to 8/31/2026 was primarily driven by a -30.0% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 8312026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.53 | 9.39 | -30.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 822 | 833 | 1.3% |
| P/S Multiple | 0.7 | 0.5 | -30.0% |
| Shares Outstanding (Mil) | 40 | 41 | -2.2% |
| Cumulative Contribution | -30.6% |
Market Drivers
2/28/2026 to 8/31/2026| Return | Correlation | |
|---|---|---|
| OFIX | -30.6% | |
| Market (SPY) | 12.1% | 13.5% |
| Sector (XLV) | 6.9% | 32.2% |
Fundamental Drivers
The -37.3% change in OFIX stock from 8/31/2025 to 8/31/2026 was primarily driven by a -37.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 8312026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.98 | 9.39 | -37.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 809 | 833 | 3.0% |
| P/S Multiple | 0.7 | 0.5 | -37.0% |
| Shares Outstanding (Mil) | 40 | 41 | -3.4% |
| Cumulative Contribution | -37.3% |
Market Drivers
8/31/2025 to 8/31/2026| Return | Correlation | |
|---|---|---|
| OFIX | -37.3% | |
| Market (SPY) | 19.9% | 19.4% |
| Sector (XLV) | 25.7% | 32.8% |
Fundamental Drivers
The -55.6% change in OFIX stock from 8/31/2023 to 8/31/2026 was primarily driven by a -64.5% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 8312026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.16 | 9.39 | -55.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 598 | 833 | 39.2% |
| P/S Multiple | 1.3 | 0.5 | -64.5% |
| Shares Outstanding (Mil) | 37 | 41 | -10.1% |
| Cumulative Contribution | -55.6% |
Market Drivers
8/31/2023 to 8/31/2026| Return | Correlation | |
|---|---|---|
| OFIX | -55.6% | |
| Market (SPY) | 76.3% | 32.4% |
| Sector (XLV) | 34.0% | 33.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OFIX Return | -28% | -34% | -34% | 30% | -13% | -36% | -77% |
| Peers Return | 1% | -3% | -1% | 12% | 12% | 6% | 28% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| OFIX Win Rate | 33% | 33% | 50% | 58% | 33% | 38% | |
| Peers Win Rate | 52% | 55% | 48% | 50% | 52% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OFIX Max Drawdown | -40% | -60% | -57% | -19% | -46% | -45% | |
| Peers Max Drawdown | -22% | -27% | -26% | -15% | -22% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SYK, MDT, ZBH, GMED, JNJ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/31/2026 (YTD)
How Low Can It Go
| Event | OFIX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -50.9% | -9.5% |
| % Gain to Breakeven | 103.6% | 10.5% |
| Time to Breakeven | 364 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.6% | -33.7% |
| % Gain to Breakeven | 102.5% | 50.9% |
| Time to Breakeven | 342 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -13.4% | -19.2% |
| % Gain to Breakeven | 15.4% | 23.8% |
| Time to Breakeven | 44 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -20.0% | -3.7% |
| % Gain to Breakeven | 25.1% | 3.9% |
| Time to Breakeven | 92 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -19.5% | -12.2% |
| % Gain to Breakeven | 24.3% | 13.9% |
| Time to Breakeven | 28 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -17.7% | -6.8% |
| % Gain to Breakeven | 21.5% | 7.3% |
| Time to Breakeven | 166 days | 15 days |
In The Past
Orthofix Medical's stock fell -2.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OFIX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -50.9% | -9.5% |
| % Gain to Breakeven | 103.6% | 10.5% |
| Time to Breakeven | 364 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -50.6% | -33.7% |
| % Gain to Breakeven | 102.5% | 50.9% |
| Time to Breakeven | 342 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -20.0% | -3.7% |
| % Gain to Breakeven | 25.1% | 3.9% |
| Time to Breakeven | 92 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -38.1% | -0.2% |
| % Gain to Breakeven | 61.5% | 0.2% |
| Time to Breakeven | 174 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -28.0% | -17.9% |
| % Gain to Breakeven | 38.9% | 21.8% |
| Time to Breakeven | 334 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -22.9% | -15.4% |
| % Gain to Breakeven | 29.7% | 18.2% |
| Time to Breakeven | 285 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -85.0% | -53.4% |
| % Gain to Breakeven | 567.6% | 114.4% |
| Time to Breakeven | 3468 days | 1085 days |
In The Past
Orthofix Medical's stock fell -2.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 2.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Orthofix Medical (OFIX)
Orthofix Medical Inc. (OFIX) is a global medical device and biologics company focused on musculoskeletal health. The company develops, manufactures, and distributes a wide range of specialized products used in spinal and orthopedic surgical procedures and therapeutic treatments across the United States, Europe, Brazil, and other international markets.
The company's business is organized into two main segments: Global Spine and Global Orthopedics. The Global Spine segment provides bone growth stimulator devices designed to enhance bone fusion and treat fractures, as well as motion preservation and fixation implants for spinal surgeries. This segment also offers various products and biologic solutions, including synthetic materials, to address a spectrum of spinal and orthopedic conditions. The Global Orthopedics segment focuses on products for fracture repair, deformity correction, and bone reconstruction procedures.
Orthofix Medical primarily serves healthcare providers, including physicians, hospitals, ambulatory surgery centers, and integrated health delivery systems. The company reaches its customers through a distribution network comprising direct sales representatives, independent distributors, and employed and independent sales representatives to ensure its specialized medical devices and biologics are available where needed.
AI Analysis | Feedback
Zimmer Biomet, but concentrated on devices and biologics for spine and orthopedic bone repair.
A Stryker that specializes in medical devices for spine and orthopedic bone healing.
AI Analysis | Feedback
- Bone Growth Stimulator Devices: Devices designed to enhance bone fusion and treat non-spinal and appendicular fractures.
- Spinal Motion Preservation and Fixation Implants: A portfolio of implant products used in surgical procedures of the spine.
- Spinal and Orthopedic Biologic Solutions: Products and tissue forms, including regenerative non-tissue biologics, that allow physicians to treat a range of spinal and orthopedic conditions.
- Orthopedic Fracture Repair and Deformity Correction Products: Orthopedic products utilized in fracture repair, deformity correction, and bone reconstruction procedures.
AI Analysis | Feedback
Orthofix Medical Inc. (OFIX) sells its medical devices and biologics primarily to other organizations within the healthcare industry, rather than directly to individual patients. Due to the fragmented nature of the healthcare market and typical industry disclosure practices, Orthofix does not publicly name specific major customer companies (such as individual hospital chains or large purchasing organizations) that constitute a significant portion of its revenue.
However, based on the company's description, its customer base primarily consists of the following categories of healthcare providers and entities:
- Physicians (and their associated practices)
- Hospitals
- Ambulatory Surgery Centers
- Integrated Health Delivery Systems
- Other purchasing organizations within the healthcare sector
These entities purchase Orthofix's products for use in surgical procedures, fracture repair, deformity correction, bone reconstruction, and therapeutic treatments.
AI Analysis | Feedback
AI Analysis | Feedback
Massimo Calafiore, President and Chief Executive Officer
Massimo Calafiore currently serves as Orthofix President and Chief Executive Officer and as a member of the Orthofix Board of Directors. Previously, Mr. Calafiore served as Chief Executive Officer of LimaCorporate S.p.A., a global orthopedics company that was acquired by Enovis Corporation. Prior to LimaCorporate, he was the Executive Vice President and Chief Commercial Officer of NuVasive, Inc. While at NuVasive, Mr. Calafiore led several functions including product marketing, research and development, and enabling technologies. He also served as President of NuVasive Specialized Orthopedics (formerly Ellipse Technologies). Earlier in his career, Mr. Calafiore worked for Waldemar Link GmbH & Co. KG, holding various leadership roles across Orthopedics, Lower Extremities, and Spine. He possesses a track record in value creation, global business leadership, and integration expertise. He holds an M.Sc. in Mechanical Engineering from the University of Catania and an MBA from New York University.
Julie Andrews, Chief Financial Officer
Julie Andrews joined Orthofix in 2024 as Chief Financial Officer. Ms. Andrews previously served as CFO for Smart Wires Technology, a global transmission grid technology company. Prior to this role, she was the Senior Vice President, Global Finance for Wright Medical Group, a global medical device company that was acquired by Stryker in 2020. Ms. Andrews also spent many years in roles of increasing responsibility at Medtronic Inc., including Vice President of Finance for the Spine and Biologics division. Early in her career, she served as a Senior Financial Analyst for Thomas & Betts and as an auditor for Thomas Havey, LLC. She played key leadership roles in several successful mergers and acquisitions at Wright Medical. Ms. Andrews served as an Independent Director for Priveterra Acquisition Corp. from 2021 to 2023. She currently serves on the board and as chair of the audit committee of RxSight, Inc. Ms. Andrews holds a Bachelor of Science in Accounting from Indiana University.
Patrick Fisher, President of Global Orthopedics
Patrick Fisher joined the Orthofix Executive Leadership Team in 2024 as the President of Global Orthopedics. Mr. Fisher previously served as Vice President and General Manager of the Foot and Ankle business unit with Stryker Corporation. Prior to his tenure at Stryker, Mr. Fisher served as the President of Lower Extremity and Biologics for Wright Medical Technology, which was acquired by Stryker in 2020. He joined Wright Medical in 2002 and held multiple roles of increasing responsibility, including Vice President of U.S. Sales.
Max Reinhardt, President of Global Spine
Max Reinhardt joined the Orthofix Executive Leadership Team in 2024 as the President of Global Spine. Mr. Reinhardt is responsible for leading SeaSpine, the Company's global spine and biologics business. His experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at Johnson & Johnson, including serving as Worldwide President, DePuy Synthes Spine, where he achieved the number two market share position in the competitive spine market.
Lucas Vitale, Chief People and Business Operations Officer
Lucas Vitale was appointed Chief People and Business Operations Officer at Orthofix in March 2024. In this pivotal role, Mr. Vitale supports the leadership team in shaping and executing the Company's integration and business transformation strategies. He oversees core shared services functions including Human Resources, Global Information Services, Global Corporate Marketing and U.S. Facility Management and Safety.
AI Analysis | Feedback
Here are the key risks to Orthofix Medical (symbol: OFIX):
- Financial Strain and Integration Challenges Post-Merger: Orthofix Medical Inc. faces significant financial challenges and risks associated with its merger with SeaSpine Holdings Corporation in January 2023. The integration process is complex and costly, leading to negative profitability, high leverage, and a precarious financial position. The company's Net Debt/EBITDA ratio is over 4.0x, and its Altman Z-Score of 1.17 places it in the "distress zone," implying a possibility of bankruptcy within the next two years. Orthofix has reported ongoing net losses and negative free cash flow, with analysts not expecting profitability in the near term. The success of the merger hinges on its ability to realize projected cost synergies, cross-sell products, and reduce its substantial debt load.
- Intense Market Competition and Innovation Pressure: The medical technology industry in which Orthofix operates is highly competitive. The company faces stiff competition from larger players like Medtronic and Globus Medical, which hold significant market share in key segments such as spine. Rivalry is driven by continuous innovation, clinical data, and the strength of sales forces, requiring Orthofix to consistently invest in research and development and effective market penetration strategies. Furthermore, the threat of non-surgical treatments gaining traction and fierce price competition in commoditized segments of spinal hardware add to the competitive pressure.
- Regulatory and Compliance Risks: As a medical device and biologics company, Orthofix Medical Inc. is subject to rigorous and evolving regulations by governmental authorities globally. Changes in regulations for product approvals and compliance can significantly impact product launch timelines and market access. Historically, Orthofix has faced issues, including accounting failures and Foreign Corrupt Practices Act (FCPA) violations in 2017, underscoring the ongoing importance of robust compliance programs. Current risk areas include government reimbursement practices and potential illegal remuneration. The potential reclassification of bone growth stimulator devices from Class III to Class II by the FDA also represents a specific regulatory uncertainty.
AI Analysis | Feedback
AI Analysis | Feedback
Bone Growth Therapies
For its Bone Growth Therapies segment, which includes bone growth stimulator devices, Orthofix Medical estimates a total addressable market of approximately $0.6 billion globally for the period of 2026–2028, with an expected market growth rate of 2%–3%. Broader market research indicates that the global bone growth stimulator market was valued at approximately $1.70 billion in 2024 and is projected to reach $2.63 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.67% from 2025 to 2032. In the U.S. specifically, the bone growth stimulator market was valued at $0.66 billion (USD 660 million) in 2024 and is expected to reach $0.99 billion by 2032, with a CAGR of 5.33% over the forecast period of 2025-2032.
Spinal Implants
Orthofix Medical estimates its addressable market for Spinal Implants to be around $10.1 billion globally for 2026–2028, with an anticipated market growth rate of 3%–4%. More broadly, the global spinal implants and devices market was estimated at $13.91 billion in 2024 and is projected to reach $23.13 billion by 2033, growing at a CAGR of 6.0% from 2025 to 2033. The U.S. spinal implants market alone was valued at $6.6 billion in 2024, with projections for a CAGR of 3.5% between 2025 and 2034. Orthofix also targets a $2 billion U.S. pedicle screw market.
Biologics
For its Biologics offerings, Orthofix Medical estimates a total addressable market of approximately $2.1 billion globally for 2026–2028, with an expected market growth rate of 2%–3%. The global orthobiologics market was valued at around $6.8 billion in 2023 and is estimated to grow at a 5.7% CAGR from 2024 to 2032. In North America, the orthobiologics market accounted for $3 billion in revenue in 2023. The U.S. orthobiologics market generated a revenue of $2,418.7 million (approximately $2.42 billion) in 2024 and is expected to reach $3,336.1 million (approximately $3.34 billion) by 2033, at a CAGR of 3.6% from 2025 to 2033.
Limb Reconstruction (formerly Orthopedics)
Orthofix Medical identifies a $2.6 billion opportunity globally for its Limb Reconstruction business (formerly Orthopedics), which focuses on limb preservation, limb lengthening, complex fracture management, and extremity deformity correction, for 2026–2028, with an expected market growth rate of 5%–6%. The broader global orthopedic trauma devices market, which includes fracture repair, was valued at approximately $11.3 billion in 2024 and is expected to reach around $20.8 billion by 2034, growing at a CAGR of 6.3% from 2025 to 2034. North America led this market in 2024, achieving over a 42.9% share with revenue of $4.8 billion. The U.S. trauma fixation devices market, a sub-segment, was valued at $4.7 billion in 2024 and is expected to reach $6.2 billion in 2034, growing at a CAGR of 2.8% during the forecast period.
Enabling Technologies
For Enabling Technologies, which includes their 7D FLASH navigation system, Orthofix Medical estimates a global addressable market of approximately $0.4 billion for 2026–2028, with a projected market growth rate of 10%–12%.
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- In January 2023, Orthofix completed a merger of equals with SeaSpine Holdings Corporation, resulting in the issuance of Orthofix common stock to SeaSpine shareholders.
- SeaSpine shareholders received 0.4163 shares of Orthofix common stock for each share of SeaSpine common stock owned.
- The acquisition of SeaSpine was valued at approximately $280 million.
Outbound Investments
- Orthofix Medical Inc. completed a merger of equals with SeaSpine Holdings Corporation in January 2023.
- The acquisition of SeaSpine Holdings Corporation was valued at approximately $280 million.
- This merger created a combined company focused on global spine and orthopedics, aiming to leverage integrated capabilities for future growth.
Capital Expenditures
- Capital expenditures for the full year 2025 were approximately $34.6 million.
- Capital expenditures for the full year 2024 were approximately $34.9 million.
- Orthofix projects capital expenditures for 2026 to be between $45 million and $50 million, primarily focused on reinvesting in the business to enhance commercial channels and support growth initiatives.
Peer Outperformance in Life Sciences Tools & Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| OFIX | Orthofix Medical | 12.3% | -6.2x | -37.3% | -55.9% | -78.1% | — |
| CDNA | CareDx | 15.1% | 23.2x | 266.8% | 415.0% | -33.6% | +44pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 11.8% | 89.7% | 134.2% | CAH 399% · MCK 346% · COR 178% |
| Managed Health Care | 8 | 28.5% | -0.9% | 2.2% | OSCR 91% · HQY 49% · ELV 14% |
| Health Care Services | 20 | 18.2% | 44.2% | -2.8% | HIMS 264% · RDNT 146% · DGX 72% |
| Health Care Equipment | 51 | -4.1% | -7.5% | -21.0% | POCI 10650% · UFPT 332% · GKOS 208% |
| Health Care Facilities | 24 | 5.8% | -4.9% | -21.2% | THC 255% · NHC 234% · ENSG 110% |
| Health Care Supplies | 12 | 31.8% | -15.9% | -37.2% | LNTH 277% · HAE 62% · MMSI 26% |
| Pharmaceuticals | 63 | -2.0% | 3.8% | -39.9% | LQDA 2335% · INDV 1177% · ETON 1051% |
| Life Sciences Tools & Services ← | 108 | 3.4% | -32.0% | -70.4% | SNWV 1814% · MEDP 216% · AXGN 192% |
| Health Care Technology | 20 | -23.5% | -59.5% | -76.7% | SPOK 72% · HSTM -3% · VEEV -14% |
| Biotechnology | 365 | 10.0% | -26.8% | -77.5% | BRTX 101100% · DNTH 1517% · CELZ 1514% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | - |
| Mkt Cap | 67.7 |
| Rev LTM | 17,173 |
| Op Inc LTM | 3,502 |
| FCF LTM | 3,052 |
| FCF 3Y Avg | 2,575 |
| CFO LTM | 3,634 |
| CFO 3Y Avg | 3,106 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.5% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 6.3% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Inc Chg LTM | 20.9% |
| Op Inc Chg 3Y Avg | 11.5% |
| Op Mgn LTM | 20.1% |
| Op Mgn 3Y Avg | 18.4% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 20.9% |
| CFO/Rev 3Y Avg | 20.7% |
| FCF/Rev LTM | 17.3% |
| FCF/Rev 3Y Avg | 16.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Global Spine | 688 | 675 | 631 | 353 | 359 |
| Global Limb Reconstruction | 135 | 124 | 115 | 108 | 106 |
| Total | 822 | 799 | 747 | 461 | 464 |
| $ Mil | 2015 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|
| BioStim | 68 | ||||
| Extremity Fixation | 29 | ||||
| Biologics | 27 | ||||
| Spine Fixation | 9 | ||||
| Corporate | -124 | -17 | -28 | ||
| Orthopedics Products | 13 | ||||
| Spine Products | 81 | ||||
| Orthopedics | 12 | ||||
| Spine | 47 | ||||
| Sports Medicine | 1 | ||||
| Breg | 10 | 13 | |||
| Domestic | 71 | 68 | |||
| Eliminations | -0 | 1 | |||
| Group Activities | -18 | -21 | |||
| International | 20 | 18 | |||
| Spinal Implants and Biologics | 6 | -14 | |||
| Total | 9 | 77 | 33 | 89 | 64 |
| $ Mil | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
| Breg | 152 | 164 | 172 | ||
| International | 151 | 161 | 146 | ||
| Domestic | 132 | 116 | 111 | ||
| Spinal Implants and Biologics | 132 | 134 | |||
| Group Activities | 36 | 13 | 11 | 25 | |
| Eliminations | -0 | 1 | |||
| Blackstone | 122 | ||||
| Americas Blackstone | 405 | 25 | |||
| Americas Breg | 180 | 182 | |||
| Americas Orthofix | 118 | 101 | |||
| International Orthofix | 178 | 171 | |||
| Total | 604 | 590 | 562 | 881 | 503 |
Price Behavior
| Market Price | $9.39 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 04/24/1992 | |
| Distance from 52W High | -42.1% | |
| 50 Days | 200 Days | |
| DMA Price | $10.70 | $12.43 |
| DMA Trend | down | up |
| Distance from DMA | -12.2% | -24.5% |
| 3M | 1YR | |
| Volatility | 65.5% | 46.9% |
| Downside Capture | 66.35 | 110.36 |
| Upside Capture | 68.83 | 32.58 |
| Correlation (SPY) | 1.4% | 18.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.31 | 0.85 | 0.09 | 0.55 | 0.71 | 1.02 |
| Up Beta | 0.29 | -0.64 | -1.48 | 0.33 | 0.78 | 0.75 |
| Down Beta | 0.60 | -0.25 | 0.01 | 0.20 | 0.63 | 0.96 |
| Up Capture | -4% | 163% | 66% | 20% | 24% | 83% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 9 | 21 | 32 | 61 | 124 | 365 |
| Down Capture | 554% | 188% | 68% | 124% | 107% | 109% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 20 | 30 | 64 | 123 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OFIX | |
|---|---|---|---|---|
| OFIX | -36.4% | 46.8% | -0.82 | - |
| Sector ETF (XLV) | 26.7% | 16.0% | 1.29 | 32.9% |
| Equity (SPY) | 19.3% | 12.8% | 1.11 | 19.2% |
| Gold (GLD) | 29.8% | 29.0% | 0.89 | 0.6% |
| Commodities (DBC) | 41.3% | 20.4% | 1.58 | -9.4% |
| Real Estate (VNQ) | 9.2% | 13.7% | 0.40 | 29.4% |
| Bitcoin (BTCUSD) | -30.9% | 43.7% | -0.72 | 3.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OFIX | |
|---|---|---|---|---|
| OFIX | -25.4% | 46.1% | -0.48 | - |
| Sector ETF (XLV) | 6.2% | 15.1% | 0.23 | 33.3% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 35.3% |
| Gold (GLD) | 19.4% | 18.7% | 0.84 | 1.7% |
| Commodities (DBC) | 11.0% | 19.5% | 0.44 | 2.4% |
| Real Estate (VNQ) | 1.9% | 18.9% | -0.00 | 36.2% |
| Bitcoin (BTCUSD) | 9.5% | 52.7% | 0.36 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OFIX | |
|---|---|---|---|---|
| OFIX | -14.0% | 40.9% | -0.23 | - |
| Sector ETF (XLV) | 10.5% | 16.7% | 0.51 | 36.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 40.5% |
| Gold (GLD) | 12.3% | 16.3% | 0.62 | 3.0% |
| Commodities (DBC) | 7.6% | 18.1% | 0.34 | 10.9% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 37.0% |
| Bitcoin (BTCUSD) | 63.4% | 66.2% | 1.03 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/14/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -14.6% | -15.4% | |
| 5/5/2026 | 3.6% | -2.8% | -19.1% |
| 2/24/2026 | -6.2% | -1.6% | -13.8% |
| 11/4/2025 | -7.4% | -6.4% | -1.0% |
| 8/5/2025 | 13.5% | 19.3% | 35.9% |
| 5/6/2025 | -10.9% | -8.2% | -19.5% |
| 2/25/2025 | -3.5% | -6.4% | -9.0% |
| 11/7/2024 | -1.0% | 1.3% | 1.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 12 | 13 |
| # Negative | 16 | 16 | 14 |
| Median Positive | 6.8% | 5.3% | 9.2% |
| Median Negative | -5.5% | -6.6% | -11.8% |
| Max Positive | 19.5% | 19.3% | 35.9% |
| Max Negative | -14.6% | -15.4% | -20.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -14.6% | -15.4% | |
| 5/5/2026 | 3.6% | -2.8% | -19.1% |
| 2/24/2026 | -6.2% | -1.6% | -13.8% |
| 11/4/2025 | -7.4% | -6.4% | -1.0% |
| 8/5/2025 | 13.5% | 19.3% | 35.9% |
| 5/6/2025 | -10.9% | -8.2% | -19.5% |
| 2/25/2025 | -3.5% | -6.4% | -9.0% |
| 11/7/2024 | -1.0% | 1.3% | 1.2% |
| 8/6/2024 | 19.5% | 9.9% | 13.8% |
| 5/7/2024 | 3.2% | 12.0% | 3.9% |
| 3/5/2024 | 8.7% | 8.1% | 9.2% |
| 1/9/2024 | -2.8% | -8.8% | -0.3% |
| 11/8/2023 | -10.4% | -9.6% | -0.8% |
| 8/8/2023 | 13.3% | 4.7% | 4.5% |
| 5/9/2023 | 1.8% | -1.5% | 7.6% |
| 3/6/2023 | -4.7% | -14.0% | -14.7% |
| 1/9/2023 | -6.6% | -4.0% | 10.3% |
| 11/3/2022 | -4.4% | 4.5% | 30.5% |
| 8/5/2022 | -7.8% | -6.8% | -20.9% |
| 5/6/2022 | -8.3% | -14.8% | -11.8% |
| 2/25/2022 | 1.3% | 2.9% | 0.4% |
| 1/10/2022 | 6.7% | 6.0% | 2.3% |
| 11/5/2021 | -2.9% | -12.2% | -16.3% |
| 8/6/2021 | 6.8% | 4.2% | 12.4% |
| 4/30/2021 | -0.5% | -1.7% | -8.7% |
| 2/26/2021 | 0.2% | -2.8% | -7.3% |
| 11/5/2020 | 14.3% | 10.5% | 10.8% |
| 8/6/2020 | -0.3% | 3.3% | -11.8% |
| SUMMARY STATS | |||
| # Positive | 12 | 12 | 13 |
| # Negative | 16 | 16 | 14 |
| Median Positive | 6.8% | 5.3% | 9.2% |
| Median Negative | -5.5% | -6.6% | -11.8% |
| Max Positive | 19.5% | 19.3% | 35.9% |
| Max Negative | -14.6% | -15.4% | -20.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 04/30/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 10/28/2019 | 10-Q |
Recent Forward Guidance
Updated 8/6/2026Latest: Q2 2026 Earnings Reported 8/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales | 845.00 Mil | 850.00 Mil | 855.00 Mil | -0.6% | Lowered | Guidance: 855.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 95.00 Mil | 96.50 Mil | 98.00 Mil | Raised | Guidance: 96.50 Mil for 2026 | ||
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net sales | 850.00 Mil | 855.00 Mil | 860.00 Mil | 0 | Affirmed | Guidance: 855.00 Mil for 2026 | |
| 2026 Non-GAAP adjusted EBITDA | 95.00 Mil | 96.50 Mil | 98.00 Mil | 0 | Affirmed | Guidance: 96.50 Mil for 2026 | |
| 2026 Free cash flow | |||||||
Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 850.00 Mil | 855.00 Mil | 860.00 Mil | 5.3% | Higher New | Guidance: 812.00 Mil for 2025 | |
| 2026 Non-GAAP Adjusted EBITDA | 95.00 Mil | 96.50 Mil | 98.00 Mil | 13.5% | Higher New | Guidance: 85.00 Mil for 2025 | |
| 2026-2028 Net Sales CAGR | 0.07 | 0.07 | 0.07 | ||||
Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Pro forma net sales | 810.00 Mil | 812.00 Mil | 814.00 Mil | 0 | Affirmed | Guidance: 812.00 Mil for 2025 | |
| 2025 Pro forma non-GAAP adjusted EBITDA | 84.00 Mil | 85.00 Mil | 86.00 Mil | 1.2% | Raised | Guidance: 84.00 Mil for 2025 | |
Insider Activity
Updated 8/20/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fisher, Patrick | President, Global Limb Recon | Direct | Sell | 8202026 | 10.09 | 1,295 | 13,067 | 516,800 | Form |
| 2 | Juniper, Investment Company, Llc | By: Juniper Multi-Strategy Fund, L.P. | Sell | 8182026 | 10.01 | 20,000 | 200,260 | 850,364 | Form | |
| 3 | Juniper, Investment Company, Llc | By: Juniper Multi-Strategy Fund, L.P. | Sell | 8182026 | 10.38 | 19,500 | 202,484 | 674,179 | Form | |
| 4 | McPherron, Aviva | Pres, Global Ops & Qual | Direct | Sell | 6222026 | 9.38 | 3,670 | 34,425 | 622,175 | Form |
| 5 | Juniper, Investment Company, Llc | By: Juniper Targeted Opportunity Fund, L.P. | Sell | 5292026 | 10.70 | 242,000 | 2,589,206 | 37,032,242 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fisher, Patrick | President, Global Limb Recon | Direct | Sell | 8202026 | 10.09 | 1,295 | 13,067 | 516,800 | Form |
| 2 | Juniper, Investment Company, Llc | By: Juniper Multi-Strategy Fund, L.P. | Sell | 8182026 | 10.01 | 20,000 | 200,260 | 850,364 | Form | |
| 3 | Juniper, Investment Company, Llc | By: Juniper Multi-Strategy Fund, L.P. | Sell | 8182026 | 10.38 | 19,500 | 202,484 | 674,179 | Form | |
| 4 | McPherron, Aviva | Pres, Global Ops & Qual | Direct | Sell | 6222026 | 9.38 | 3,670 | 34,425 | 622,175 | Form |
| 5 | Juniper, Investment Company, Llc | By: Juniper Targeted Opportunity Fund, L.P. | Sell | 5292026 | 10.70 | 242,000 | 2,589,206 | 37,032,242 | Form | |
| 6 | Engine, Capital Management, LP | By: Engine Capital, L.P. | Buy | 5072026 | 12.18 | 27,288 | 332,391 | 46,878,826 | Form | |
| 7 | Engine, Capital Management, LP | By: Engine Lift Capital, LP | Buy | 5072026 | 12.18 | 2,712 | 33,034 | 4,658,560 | Form | |
| 8 | Engine, Capital Management, LP | By: Engine Capital, L.P. | Buy | 5072026 | 12.23 | 38,154 | 466,547 | 46,726,673 | Form | |
| 9 | Engine, Capital Management, LP | By: Engine Lift Capital, LP | Buy | 5072026 | 12.23 | 3,792 | 46,369 | 4,643,436 | Form | |
| 10 | Engine, Capital Management, LP | By: Engine Capital, L.P. | Buy | 5072026 | 11.99 | 110,039 | 1,319,676 | 45,370,333 | Form | |
| 11 | Engine, Capital Management, LP | By: Engine Lift Capital, LP | Buy | 5072026 | 11.99 | 2,911 | 34,911 | 4,508,645 | Form | |
| 12 | Cedron, Jorge Andres | CLO | Direct | Sell | 4202026 | 12.82 | 3,743 | 47,985 | 756,457 | Form |
| 13 | Vitale, Lucas | CP&BOO | Direct | Sell | 3192026 | 11.92 | 4,269 | 50,886 | 1,912,552 | Form |
| 14 | Capps, Vickie L | Direct | Buy | 3102026 | 12.45 | 2,500 | 31,124 | 343,422 | Form | |
| 15 | Capps, Vickie L | Direct | Buy | 3102026 | 12.48 | 2,500 | 31,200 | 313,061 | Form | |
| 16 | Engine, Capital Management, LP | By: Engine Capital, L.P. | Buy | 2262026 | 12.96 | 9,959 | 129,103 | 47,615,761 | Form | |
| 17 | Engine, Capital Management, LP | By: Engine Lift Capital, LP | Buy | 2262026 | 12.96 | 3,102 | 40,212 | 4,835,802 | Form | |
| 18 | Engine, Capital Management, LP | By: Engine Capital, L.P. | Buy | 2262026 | 12.55 | 117,076 | 1,468,777 | 45,955,835 | Form | |
| 19 | Engine, Capital Management, LP | By: Engine Lift Capital, LP | Buy | 2262026 | 12.55 | 7,721 | 96,864 | 4,640,994 | Form | |
| 20 | Andrews, Julie | CFO | Direct | Sell | 1212026 | 14.38 | 4,873 | 70,074 | 834,601 | Form |
| 21 | Calafiore, Massimo | President & CEO | Direct | Sell | 1132026 | 15.21 | 9,797 | 149,050 | 3,305,000 | Form |
| 22 | Calafiore, Massimo | President & CEO | Direct | Sell | 1132026 | 15.82 | 9,600 | 151,906 | 3,592,472 | Form |
| 23 | Fisher, Patrick | President, Global Orthopedics | Direct | Sell | 8202025 | 14.21 | 1,996 | 28,363 | 427,948 | Form |
Investor Activity (13F)
Updated Sep 1, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.